MedElevator
Войти в исследования Respiratory medicine · 2026
Association of inhaled corticosteroid use with first Pseudomonas aeruginosa isolation in eosinophilic bronchiectasis: a multicenter retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yawen, Liu Runqing, Bian Xiujuan, Zhang Guoqing, Hou Lili, Ren Jie, Ben Suqin, Wu Jiayue, Tang Rong, Liu Xiaoyan, Ding Ying, Ouyang Wenjuan, Zhao Meihua, Wang Wenping, Gao Jianwei, Shao Ping, Liao Ruomin, Zhang Min, Ding Fengming
Аннотация
BACKGROUND: The use of inhaled corticosteroids (ICS) in bronchiectasis patients with eosinophilic inflammation is controversial due to the potential risk of bronchial or pulmonary infection. This study examined the association between ICS use and first Pseudomonas aeruginosa isolation across strata of blood eosinophil count (BEC).
METHODS: A multicenter retrospective study was conducted in patients with bronchiectasis, who were classified according to baseline BEC at cohort entry: HighBEC (≥300 cells/μL), InterBEC (100-299 cells/μL), and LowBEC (<100 cells/μL). ICS use was identified from prescription records, and first P. aeruginosa isolation was defined as the first positive culture for P. aeruginosa from a lower respiratory tract sample after cohort entry. Multivariate Cox proportional hazards regression was used to quantify the risk of first P. aeruginosa isolation associated with ICS use.
RESULTS: Of 1900 bronchiectasis patients assessed, 719 were analyzed: 194 (27.0%) received ICS, 525 (73.0%) did not. During follow-up, P. aeruginosa was detected in 69 (9.6%) patients. After adjustment for potential confounders and disease severity indicators, ICS use was associated with a significantly higher risk of first P. aeruginosa isolation in patients with BEC ≥ 100 cells/μL, using no ICS as reference (HighBEC: adjusted HR 4.15, 95% CI 1.29-13.38, P = 0.0172; InterBEC: adjusted HR 3.13, 95% CI 1.56-6.27, P = 0.0013), but not in LowBEC patients (adjusted HR 0.48, 95% CI 0.08-2.79, P = 0.4160). Propensity-matched analyses supported these findings.
CONCLUSION: ICS use was associated with an increased risk of first P. aeruginosa isolation in eosinophilic bronchiectasis, suggesting caution when prescribing ICS to these patients.
METHODS: A multicenter retrospective study was conducted in patients with bronchiectasis, who were classified according to baseline BEC at cohort entry: HighBEC (≥300 cells/μL), InterBEC (100-299 cells/μL), and LowBEC (<100 cells/μL). ICS use was identified from prescription records, and first P. aeruginosa isolation was defined as the first positive culture for P. aeruginosa from a lower respiratory tract sample after cohort entry. Multivariate Cox proportional hazards regression was used to quantify the risk of first P. aeruginosa isolation associated with ICS use.
RESULTS: Of 1900 bronchiectasis patients assessed, 719 were analyzed: 194 (27.0%) received ICS, 525 (73.0%) did not. During follow-up, P. aeruginosa was detected in 69 (9.6%) patients. After adjustment for potential confounders and disease severity indicators, ICS use was associated with a significantly higher risk of first P. aeruginosa isolation in patients with BEC ≥ 100 cells/μL, using no ICS as reference (HighBEC: adjusted HR 4.15, 95% CI 1.29-13.38, P = 0.0172; InterBEC: adjusted HR 3.13, 95% CI 1.56-6.27, P = 0.0013), but not in LowBEC patients (adjusted HR 0.48, 95% CI 0.08-2.79, P = 0.4160). Propensity-matched analyses supported these findings.
CONCLUSION: ICS use was associated with an increased risk of first P. aeruginosa isolation in eosinophilic bronchiectasis, suggesting caution when prescribing ICS to these patients.